Endovascular Embolization by Transcatheter Delivery of Particles: Past, Present, and Future. by Sheth, Rahul A et al.
UCLA
UCLA Previously Published Works
Title

























Endovascular Embolization by Transcatheter Delivery
of Particles: Past, Present, and Future
Rahul A. Sheth 1, Sharjeel Sabir 1, Savitri Krishnamurthy 2, Reginald K. Avery 3,4,
Yu Shrike Zhang 3,4, Ali Khademhosseini 3,4 and Rahmi Oklu 4,5,*
1 Department of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center,
Houston, TX 77030, USA; rasheth@mdanderson.org (R.A.S.); shsabir@mdanderson.org (S.S.)
2 Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA;
skrishna@mdanderson.org
3 Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA;
avery.reginald@gmail.com (R.K.A.); yszhang@mit.edu (Y.S.Z.); alik@bwh.harvard.edu (A.K.)
4 Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA 02139, USA
5 Division of Interventional Radiology, Mayo Clinic, 5777 E Mayo Blvd, Scottsdale, AZ 85054, USA
* Correspondence: oklu.rahmi@mayo.edu; Tel./Fax: +1-480-3421650
Academic Editor: Francesco Cilurzo
Received: 16 November 2016; Accepted: 28 March 2017; Published: 3 April 2017
Abstract: Minimally invasive techniques to occlude flow within blood vessels, initially pioneered
in the 1970s with autologous materials and subsequently advanced with increasingly sophisticated
engineered biomaterials, are routinely performed for a variety of medical conditions. Contemporary
interventional radiologists have at their disposal a wide armamentarium of occlusive agents to treat
a range of disease processes through a small incision in the skin. In this review, we provide a historical
perspective on endovascular embolization tools, summarize the current state-of-the-art, and highlight
burgeoning technologies that promise to advance the field in the near future.
Keywords: biomaterials; biomedical devices; cardiovascular devices; drug delivery systems;
microspheres; microfluidics
1. Introduction
The past half-century has witnessed a tremendous expansion in the use of minimally invasive,
endovascular techniques in medicine. Interventions predicated upon real-time image guidance to
direct flexible catheters from an easily accessible, superficial blood vessel to a remote blood vessel
deep within the body have revolutionized the clinical management of diseases involving almost
every organ. A common paradigm in endovascular procedures is the performance of vascular
embolization, a technique in which an occlusive agent is delivered through a catheter to obstruct
flow within a targeted blood vessel. Embolization procedures are performed for a variety of medical
conditions including to stop bleeding from a hemorrhagic stomach ulcer or to eradicate a tumor in the
liver by blocking its blood supply. A diverse armamentarium of occlusive agents is currently clinically
available, including metallic coils, injectable glues, and embolic particles. Each category of embolic
agent is characterized by its respective strengths and weaknesses and enjoys several niche clinical
scenarios for which it is ideally suited. Embolic particles were the first embolic agent developed and
remain arguably the most versatile; moreover, they represent an ideal platform for tailored, highly
localized transcatheter delivery of therapeutics. In this review, we summarize the current methods
in the synthesis of particles and present the merits of the latest technologies such as microfluidic
technology that have tremendous potential for advancing personalized particle design.
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2. Historical Perspective on Particle Embolization Materials
Dr. Charles Dotter and his team at the Oregon Health Sciences University were the first to perform
an embolization procedure in 1970. They used an autologous blood clot as the embolic agent to control
a bleeding gastric ulcer by selective embolization of the right gastroepiploic artery in a critically
ill patient. Soon after that historic day, autologous blood clot embolization was applied to other organs
as well [1].
The preparation of fresh blood clots involves collecting fresh blood in a sterile container and
allowing a clot to form. Once this occurs, the clot is cut into various sizes. By heating clots to 56–66 ◦C
in a water bath, the lysis time is significantly prolonged. Similarly, the addition of aminocaproic acid
to fresh blood inhibits plasmin, rendering the blood clot more resistant to lysis [2]. The clot can also be
modified by adding cellulose, thrombin, or chronic clots to prolong the lysis time.
When injected, clots undergo fragmentation. This leads to distal migration, resulting in occlusion
of vessels smaller than the injected clot. While this technique has faded into obsolescence, it is worth
noting that autologous blood clots are almost completely biodegradable and cause a minimal vascular
inflammatory response, two desirable features in certain clinical settings that not all contemporary
embolization particles can claim.
A variation on autologous blood clots, autologous subcutaneous tissue and muscle have been used
as embolization materials in the past as well [2]. The tissue is harvested from the patient immediately
prior to embolization and then cut into small “meatballs” and suspended in saline. Unlike autologous
blood clots, tissue is considered to be a permanent embolic agent, though there are very limited data
on this technique [2].
The clinical need for permanent, radio-opaque embolic particles led to the evaluation of synthetic agents.
Some of the earliest embolization particles were composed of lead shot [3] and Silastic [4], an inert silicone
elastomer. The particle sizes were on the order of 1 mm and resulted in very proximal occlusion.
3. Modern Particle Embolization: Synthesis, Applications, and Limitations
3.1. Polyvinyl Alcohol Particles
Polyvinyl alcohol (PVA) is a biocompatible polymer that has been used in medicine since the 1950s.
Early applications of PVA ranged from its use as a filling material following pneumonectomy to a skin
substitute in burn patients [5].
PVA is highly compressible, and when it is dried while in compression, it will retain its
compressed shape. When it is rehydrated, PVA will expand to up to 15 times its compressed size.
PVA particles were first introduced as a transcatheter embolization tool in the 1970s [6]. PVA has
since been used in a myriad of applications in Interventional Radiology, including embolization of
arteriovenous malformations, mesenteric bleeding, primary malignancies, and bony metastases.
Upon injection, PVA particles adhere to the blood vessel wall, slowing flow and eventually leading
to thrombus. PVA additionally induces an inflammatory response characterized by angionecrosis of
the vessel wall. PVA is not biodegradable and is thus considered a permanent embolic agent. However,
recanalization of embolized vessels with PVA can occur; this may be mediated by angiogenesis within
the organized thrombus, resulting in resorption of thrombus.
The fabrication of PVA particles for embolotherapy involves shaving or rasping the surface of
a compressed block of PVA; the resultant pieces are sorted through sieves to separate the particles
based on size. A drawback of this method is the heterogeneity in size and shape of the particles.
A particle that is too large will lodge too proximally within a vessel, likely causing ineffective
embolization. Alternatively, a particle that is too small will travel too distally, increasing the risk
for end-organ damage. Examples of the latter from early formulations of PVA include facial nerve
palsy after external carotid artery embolization [7] and bladder necrosis after pelvic embolization [8].
Moreover, PVA particles have a high coefficient of friction and can aggregate. This has two undesirable
ramifications. First, the effective size of the particle increases significantly, leading to proximal rather
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than distal embolization. Second, the particles may “stick” within a microcatheter, impeding their
injection into the patient.
3.2. Gelatin Sponge
Gelatin sponge is a non-antigenic carbohydrate prepared from purified skin gelatin.
Gelatin sponge has a highly porous microscopic structure, allowing for absorption of up to 45 times
its weight in fluid [9]. Like PVA, gelatin sponge has been used in medicine for over half a century,
as it was initially introduced as a pro-coagulant for surgical patients in the 1940s. Also like PVA,
gelatin sponge has been used as a transcatheter embolic agent for a broad range of clinical applications,
including embolization of renal tumors and for emergent pelvic bleeding [6] (Figure 1). Gelatin sponge
is commercially available as a powder or a sheet that can be cut to size; the powder form contains
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Gelatin  sponge  incites a necrotizing arteritis and  foreign body  reaction  that  cause  thrombus 
formation. The inflammatory changes persist for approximately 30–45 days, after which point gelatin 
sponge as well as the induced thrombus are no longer detectable. 
Figure 1. A large benign solitary fibrous tumor of the right pleura (A) was pre-operatively embolized
with Gelfoam; (B) surgical resection photograph; (C) angiography of the right phrenic artery
demonstrated exuberant vascularity within the mass; (D) histology demonstrates fragments of Gelfoam
(acellular pink material) within blood vessels in the mass which is entirely infarcted.
There are multiple techniques of preparing gelatin sponge for embolization [10]. Variability in
technique and reliance on manual maneuvers such as cutting and pumping slurries between syringes
results in a broad, unevenly distributed mixture of particle sizes that may range from less than 500 µm
to above 2000 µm. This, in turn, limits reproducibility and predictability of where the embolic particles
will lodge in the vascular tree.
Gelatin sponge incites a necrotizing arteritis and foreign body reaction that cause thrombus
formation. The inflammatory changes persist for approximately 30–45 days, after which point gelatin
sponge as well as the induced thrombus are no longer detectable.
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While gelatin sponge is conventionally regarded as a “temporary” embolization material, there are
limited data regarding the in vivo duration of occlusion following gelatin sponge embolization.
In animal studies, the inflammatory reaction to gelatin sponge has been shown to subside by
4 months, without any trace of the material on pathology [11]. On the other hand, clinical cases
of permanent embolization following gelatin sponge administration have also been described [12].
As such, complications such as ischemia can occur. For example, buttock ischemia and bladder
gangrene have been reported following pelvic embolization with gelatin sponge [13]. Moreover,
Gelatin sponge can retain air bubbles when not properly compressed, which can promote and sustain
aerobic infectious agents and in theory lead to abscess formation [14]. The relationships between
method of gelatin sponge preparation, volume of administration, or target organ on time course of
embolization remain incompletely elucidated.
3.3. Microspheres
The development and clinical application of microspheres represents an important advancement
in narrowing embolization particle size distribution (Figures 2 and 3). Microspheres offer several
advantages over PVA particles and gelatin sponge. As opposed to the irregular shape of PVA particles,
the spherical geometry of microspheres decreases the risk of particle clumping within the microcatheter.
Additionally, there is a strong correlation between the size of the microsphere and the diameter of the
vessel at which occlusion occurs; the same cannot be said about PVA particles, as animal studies show
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Figure  2. A  frontal  lobe glioblastoma multiforme was pre‐operatively  embolized using polyvinyl 
alcohol  (PVA)  microspheres.  A  microcatheter  (A,B)  was  advanced  to  a  branch  of  the  middle 
meningeal  artery  that  supplied  the  tumor  (C).  (D)  Post‐surgical  histology  demonstrated  PVA 
(acellular  light blue mucoid material) within  the  tumoral blood vessels  in  the  tumor comprised of 
pleomorphic large tumor cells; of note, the black material represents the “liquid embolic” agent Onyx 
(Medtronic‐Covidien, Irvine, CA, USA).   
Figure 2. A frontal lobe glioblastoma multiforme was pre-operatively embolized using polyvinyl
alcohol (PVA) microspheres. A microcatheter (A,B) was advanced to a branch of the middle meningeal
artery that supplied the tumor (C). (D) Post-surgical histology demonstrated PVA (acellular light
blue mucoid material) within the tumoral blood vessels in the tumor comprised of pleomorphic large
tumor cells; of note, the black material represents the “liquid embolic” agent Onyx (Medtronic-Covidien,
Irvine, CA, USA).
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Figure  3.  A  falcine  meningioma  was  pre‐operatively  embolized  using  PVA  microspheres.  A 
microcatheter (A,B) was advanced to a branch of the middle meningeal artery supplying the tumor 
(C). Post‐surgical histology shows PVA microspheres within the tumoral tissue (D). 
Current  microspheres  commercially  available  in  the  United  States  are  composed  of  PVA 
(Contour SE, Boston Scientific, Natick, MA, USA; Bead Block and LC Bead, Biocompatibles, Farnham, 












Figure 3. A falcine meningioma was pre-operatively embolized using PVA microspheres. A microcatheter
(A,B) was advanced to a branch of the middle meningeal artery supplying the tumor (C). Post-surgical
histology shows PVA microspheres within the tumoral tissue (D).
Current microspheres commercially available in the United States are composed of PVA
(Contou SE, Boston Scientific, Natick, MA, USA; Bead Block and LC Bead, Biocompatibles, F rnham,
Surrey, UK), trisacryl-gelatin (Embosphere and EmboGold, Merit Medical Systems, South Jordan,
UT, USA), polymethylmethacrylate with a coat of polyzene-F (Embozene, Celenova, San Antonio,
TX, USA), and a super-absorbent copolymer (Quadrasphere, Merit Medical Systems, South Jordan,
UT, USA).
For example, Embospheres are made of a cross-linked tris-acryl hydrophilic copolymer
impregnated with gelatin; the role of gelatin is to facilitate endothelial adherence, thereby providing
a more co plete vascular occlusion. Microspheres are available in industry stan ard size ranges
of 200 µm, approxima e y co responding to the ize of bl od vessels accessibl by microcatheters:
100–300 µm, 300–500 µm, 500–700 µm, 700–900 µm, and 900–1200 µm. Size orting is achieved by
filtering the synthesized particles through a series of sieves, and so for a given size range, one can
expect that approximately 90%–95% of all microspheres are within the prescribed range. It is important
to note as well that there is a Gaussian distribution of particle sizes within a given range (Figure 4).
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Contour SE microspheres, which  flatten with minimal  resistance  at  low  compression  forces  [17]. 
Moreover, the elastic recovery of Embosphere is much faster than Contour SE, which can require up 
to  several  seconds  to  recover  [18];  this  phenomenon  is  likely  predicated  upon  the macroporous 
structure of Contour SE beads which allows for the extrusion of water from the microsphere upon 
compression, as opposed to the microporous structure of Embosphere and Bead Block which retains 
water.  These  properties  play  critical  roles  in  determining  the  level  of  embolization.  Given  the 
deformability  of  Contour  SE  particles,  it  follows  that  these  microspheres  result  in  more  distal 
occlusion  than  the  less deformable Bead Block and Embosphere particles. That  is, even within an 
identical size range, microspheres of different formulations will embolize vessels at different levels 
of  the  vascular  tree. The pattern  of  embolization  is  of more  than  just  academic  interest;  clinical 
evidence  has  demonstrated  that  Contour  SE  particles  result  in  higher  rates  of  partial 
devascularization of uterine fibroids compared Embosphere particles [19,20]. 
3.4. Drug Eluting Particles 
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Figure 4. Scanning electron microscopy (insert) and size distribution of poly (lactic-co-glycolic acid)
(PGLA) micr particles f bricated through conventional emulsion methods dem strate a broad range
of sizes even after filtering the particles through sieves. Reproduced with permission from [15].
Each commerci l formulation dem nstrates different c mpressibility, elasticity, and rigidity [16].
Even amongst microspheres composed of PVA, variations in their composition can have significant
impacts on their function. For example, LC Beads do not aggregate inside blood vessels as other
similarly sized PVA microspheres of differing compositions may, and as such LC Beads can result
in deeper embo ization. Additionally, Embosph re microspheres are much more igid than Contour
SE microspheres, which flatten with minimal resistance at low compression forces [17]. Moreover,
the elastic recovery of Embosphere is much faster than Contour SE, which can require up to several
seconds to recover [18]; this phenomenon is likely predicated upon the macroporous structure of
Contour SE beads which allows for th extrusio of water from th micro ph re upon compression,
as opposed to the microporous structure of Embosphere and Bead Block which retains water.
These properties play critical roles in determining the level of embolization. Given the deformability
of Contour SE particles, it follows that these microspheres result in more distal occlusion than the
less deformable Bead Block and Embosphere particles. That is, even within an identical size range,
microspheres of different formulations will embolize vessels at different levels of the vascular tree.
The pattern of embolization is of more than just academic interest; clinical evidence has demonstrated
that Contour SE particles result in higher rates of partial devascularization of uterine fibroids compared
Embosphere particles [19,20].
3.4. Drug E uting Particles
Drug eluting particles represent the next phase in the evolution of embolization particles (Figures 5
and 6). The concept of controll d drug release s no a new one, aving been first propos d in the 1960s.
Formulations of pharmacologic agents that provide a sustained release of drugs over a protracted
length of time, rather than through a single bolus dose, facilitate the diffusion of the drug through
the interstitial space and improve its concentrations at the target. However, a persistent challenge
for any sustained release system is its precise delivery to the target lesion, thereby minimizing the
systemic toxicity and maximizing the therapeutic efficacy. Interventional Radiology has taken on this
challenge, and over the past decade Interventional Radiologists have assumed an expanding role in
the locoregional administration of therapeutics. This growth has been most evident in the realm of
oncology through the advent of microspheres loaded with chemotherapeutic agents. These particles
serve as a reservoir of chemotherapy, slowly releasing the drug over time. This results in improved
penetration into the tumor as well as a decrease in systemic toxicity [21].
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Figure 5. A leiomyosarcoma metastasis to the liver was embolized with 100–300 µm, doxorubicin-eluting
microspheres to reduce tumor size and vascularity prior to surgical resection. Selective catheterization (A)
of the tumor was performed, with proper positioning confirmed by cone-beam CT (B). Post-procedure CT
(C) demonstrates no residual vascularity within the lesion. Following liver resection, microspheres were
identifie within the blood vessels in the tumor bed without any evidence of viable metastatic tumor (D).
.  .  .  ,  ,         
Figure 6. A breast cancer metastasi to the li s e bolized with 100–300 µm, doxorubicin-eluting
microspheres to reduce tumor size and vascularity prior to surgical resection. Selective catheterization
(A) of the tumor was performed, with delivery of the microspheres within the blood vessels of the
tumor (B). Post-procedure CT (D) demonstrates complete response of the tumor as indicated by fibrosis
alone without any evidence of residual tumor compared to the pre-procedure CT (C).
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The composition and functionality of drug eluting particles can be broadly divided into two
categories [22]. One class of drug eluting microspheres is composed of polymers that adsorb drugs
through ionic interactions. The archetypical particle that exhibits this mechanism of drug loading is
DC Bead (Biocompatibles, Farnham, Surrey, UK). DC Beads are commonly loaded with doxorubicin,
and the controlled release of this drug is mediated by an ion-exchange mechanism, where a positively
charged counter-ion (presumably Na+) binds to release doxorubicin from the inner surface of the bead.
Not all pharmaceuticals are amenable to this method of drug loading, however, and so it cannot be
generalized for all drugs.
A second class of drug eluting microsphere is those that behave like sponges and “soak up”
drugs in solution. Sodium acrylate polyvinyl (SAP) microspheres (Quadrasphere, Merit Medical
Systems, South Jordan, UT, USA) are an example of this category: these particles absorb aqueous
solutions to expand by up to 64 times their dry volume [22]. The limiting factor in drug loading for
a SAP microsphere is the solubility of the therapeutic agent in saline. An important drawback to this
absorption method of drug loading is that the mechanical characteristics of the particle, including size,
rigidity, and elasticity, vary as a function of their drug loading. This can lead to unpredictability in the
level of the vascular tree where embolization occurs.
4. Previewing the Future of Particle Embolization
4.1. Microfluidics
Since its inception in the 1940s, transcatheter embolization has enjoyed an increasingly
sophisticated armamentarium of injectable particles. In considering what the future holds for this
procedure, it is worthwhile to reflect upon the properties of conventional particles that show room
for improvement. First and foremost, current embolic particles, including calibrated microspheres,
are polydisperse. Bulk microparticle synthesis by emulsification followed by filtering with sieves
yields particles with a non-uniform size distribution. This variability, coupled with differences
in deformability due to particle composition, results in unpredictable depths of penetration and
sites of embolization. Another concern with modern embolization particles is the risk of non-target
embolization. This complication can occur despite appropriate operator technique and is doubly
disconcerting due to the decreased delivery of particles to the target and risk of injury to nearby
normal tissue. Finally, where the presently marketed embolization particles offer an impressive array
of options in particle size, composition, and drug delivery, no two patients are the same, and relying
on off-the-shelf products that work for most patients does not necessarily imply that they work for
all patients.
Therefore, the principal characteristics of an ideal embolization particle include a monodisperse
size distribution, specific activation within the target lesion to diminish the risk of non-target
embolization, and a customizable design that can be tailored to patients on an individual basis.
While these features would have been considered unfeasible as recently as the 1990s, innovations in
micro-fabrication are narrowing the gap between theory and reality.
One such envelope-pushing technology that is on the cusp of clinical translation is microfluidics.
Microfluidics is a discipline that resides at the convergence of physics, chemistry, and bioengineering.
It is the study of the behavior and manipulation of geometrically constrained fluids at a sub-millimeter
scale. Microfluidics systems have been investigated in the development of biodegradable, drug-bearing
microspheres, with remarkable pre-clinical success (Figure 7).
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Figure 7.  (A) Optical  image of a microfluidic  chip  featuring  two parallel droplet  formulators.  (B) 
Optical image of an in‐line droplet generating nozzle for particle formulation and emulsification. (C) 
Optical  image of  a monodisperse population  of  10 m diameter microspheres. Reproduced with 
permission from [23]. Copyright (2005) American Chemical Society. 
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Figure 7. (A) Optical image of a microfluidic chip featuring two parallel droplet formulators. (B) Optical
image of an in-line droplet generating nozzle for particle formulation and emulsification. (C) Optical
image of a monodisperse population of 10 µm diameter microspheres. Reproduced with permission
from [23]. Copyright (2005) American Chemical Society.
Designing embolization particles by microfluidics affords numerous advantages over conventional
fabrication techniques. Microfluidic systems have small footprints, are low cost, and require minimal
training to operate. They are highly tunable systems that allow a user to specify on demand the size of
microsphere generated by the system. The output from microfluidics systems is highly monodisperse
microspheres (Figure 8). These features open the door to personalized particle design and synthesis
that can be performed at the point of care.
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(C), size distribution chart shows a near “delta” function of particle size, con istent with
a monodisperse population. Reproduced with permission from [15].
oreover, given that every particle produced in a microfluidic system is the same size, no size
filtering of the generated particles is required. This results in much higher yields than standard
microsphere synthesis methods, in which size specificity is achieved by removing the large particles
through a series of filters. This can play a key role in reducing the cost of microsphere fabrication,
particularly if they are loaded with an expensive therapeutic agent.
Homogenous particle morphology also assists in predicting drug delivery in drug-eluting particles.
There are several critical parameters that impact the spatial and temporal kinetics of drug release from
microspheres. These include the rate of degradation of the microsphere, the internal architecture of the
microsphere, the solubility of the therapeutic, and the concentration of drug on the microsphere.
By standardizing the mechanical properties of all particles delivered to the patient, the rate of
drug delivery can be estimated with high fidelity, reproducibility, and consistency. Monodisperse
microspheres demonstrate slower overall rates of release compared to conventionally fabricated
polydisperse microspheres. Furthermore, larger particles release drugs at a more gradual rate than
smaller particles. Given the narrow distribution in particle size generated by microfluidic devices,
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interventional radiologists could seek to optimize delivery kinetics by using particles just at the size
limit of the desired level of embolization, as the risk of administering particles larger than desired is
essentially non-existent.
Microfluidics systems allow for flexibility in the material composition of microspheres.
Most drug-eluting particles are composed of a hydrogel, which is a three-dimensional hydrophilic
polymer that can absorb a large amount of water without losing its spherical shape. There exists
a vast array of hydrogels, including those that respond to physical or chemical stimuli such as heat,
pH, temperature, and glucose [24]. For example, thermosensitive poly (organophosphazene) hydrogels
provide a sustained release of doxorubicin; one can easily envision the synergy of such a drug-eluting
microsphere with percutaneous thermal ablation methods for the treatment of hepatic malignancies.
Thermosensitive polymers have already penetrated the endovascular surgery market and have been
used as temporary vascular occlusion devices during arterial bypass procedures [25]. In addition
to pharmacologic agents, microspheres can be loaded with biological agents through microfluidics
techniques. For example, microparticles can be loaded with viral vectors which can deliver targeted
gene therapy [26].
4.2. Tissue Engineering
Tissue engineering, like microfluidics, is another well-developed field in bioengineering that can
contribute to the improvement of particle embolization materials. Tissue engineering at its core is the
control of tissue development in vitro and in vivo. Materials previously used for particle embolization
can be redesigned with tissue engineering in mind to improve biocompatibility and functionality.
Incorporating tissue engineering into the design of embolization particles provides a framework
from which biochemical factors, through small molecule encapsulation or biomaterial design, or cells
can be delivered to actively impact the local environment surrounding an occluded vessel. The tissue
engineered particles can be coated with extracellular matrix proteins such as collagen, fibronectin,
or laminin to improve the endothelialization of embolic particles [27]. Bioactive molecules such as
tissue plasminogen activator (tPA) or aminocaproic acid can also be encapsulated in chitosan or
poly(2-hydroxyethyl methacrylate) to impact coagulation surrounding the embolic particle [28,29].
More active enzymes such as thrombin have also been encapsulated in synthetic polymer microspheres
to accelerate clotting at the site of embolism [30].
5. Conclusions
Particles for endovascular embolization have evolved from materials such as lead pellets, muscle,
fat, autologous blood clot and gelatin sponge to particles comprised of complex polymers with varying
biochemical properties which can be modified to carry therapeutic payloads. Currently available
particles span a broad spectrum of sizes, shapes, and materials and compose a versatile toolkit
applicable to a myriad of disease processes. This toolkit, and by extension the clinical utility and
applicability, is poised to expand substantially through emerging technologies that may revolutionize
the accuracy and efficacy of particles.
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